Novogen jumps as article predicts imminent cancer partnership

Novogen (NVGN) is up some 20% in premarket trading.

The move looks to be attributable to an article by SA contributor Small-Cap Momentum Advisors, who calls the stock "the most exciting opportunity ... in the biotech sector in years."

Long story short, the author cites a "hidden jewel" in the company's annual report which he says suggests "that a major pharmaceutical company with an extensive background in ovarian cancer treatment ... may partner with NVGN."

"This news could hit the tape at any moment," the author adds.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs